퇴행성 요추 디스크 질환 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 치료 유형, 투여 경로, 최종 사용자, 지역별, 경쟁(2021-2031년)

The Global Lumbar Degenerative Disc Disease Market is projected to expand significantly, from USD 9.67 billion in 2025 to USD 14.33 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.78%. This market encompasses various medical interventions, including pharmaceuticals and spinal implants like artificial discs and fusion devices, all aimed at pain management and restoring stability in the lower spine. Key growth drivers include the increasing global geriatric population and rising rates of obesity, both contributing to accelerated spinal deterioration, along with sedentary lifestyles weakening spinal musculature and elevating the incidence of lower back conditions requiring medical intervention. However, the market faces significant challenges from the high cost of spinal surgeries and restrictive reimbursement policies, which limit patient access to advanced treatments; these financial obstacles are often exacerbated by rigorous regulatory approval processes for new technologies, potentially slowing the introduction of innovative solutions, with annual spending on spine care in the U.S. alone surpassing $85 billion in 2024, according to the North American Spine Society, highlighting the substantial economic burden.

Market Driver

A key market driver is the increasing integration of robotic-assisted spinal surgery, which is transforming clinical outcomes in lumbar degenerative disc disease by improving screw placement accuracy and decreasing intraoperative radiation exposure; these advanced systems enable minimally invasive procedures, significantly shortening recovery periods and reducing surgical complications, thus boosting hospital adoption and justifying substantial capital expenditures, exemplified by Globus Medical's Q2 2024 earnings call (August 2024) reporting a 59% year-over-year growth in robot unit placements, and Medtronic's Cranial and Spinal Technologies division generating $1.2 billion in quarterly revenue in Q2 FY2025 (November 2024) largely due to integrated enabling technologies and spinal implants. Concurrently, the accelerating growth of the global geriatric population is a crucial demographic driver, as natural aging inherently causes intervertebral disc and spinal structure deterioration; with rising global life expectancy, increased mechanical stress on the lumbar spine leads to a higher incidence of complex conditions such as spinal stenosis and spondylolisthesis, necessitating medical intervention, a significant public health issue highlighted by a November 2024 article in Frontiers in Public Health stating that around 628.8 million people globally suffered from low back pain in 2021, a number consistently increasing with aging demographics, thus ensuring a continuous demand for both therapeutic and surgical management strategies for lumbar degenerative disc disease across all healthcare systems.

Market Challenge

The Global Lumbar Degenerative Disc Disease Market faces considerable obstacles due to the rising costs of spinal procedures and a progressively stricter reimbursement landscape; healthcare systems, aiming to control expenses, impose rigorous criteria for surgical approval, leading to frequent claim rejections and delayed payments for advanced spinal interventions, a financial strain that compels hospitals and surgical centers to restrict their stock of premium implants and defer the adoption of newer, more expensive technologies, thereby impeding market growth. Consequently, the financial feasibility of performing complex lumbar surgeries is decreasing for many providers, as reimbursement rates often fail to match the increasing operational costs of surgery, causing the adoption of innovative fusion devices and artificial discs to stall; data from the American Academy of Orthopaedic Surgeons in 2025 indicated a 26.2% decrease in average reimbursements for orthopedic surgeries over an eight-year period, a significant reduction in financial compensation that forces medical professionals to prioritize cost control over technological progress, directly hindering revenue generation for industry participants.

Market Trends

A prominent market trend is the shift of lumbar procedures to ambulatory surgery centers (ASCs), driven by the economic necessity to lower healthcare costs and advancements in minimally invasive techniques that enable safe, same-day discharge; this transition moves routine spinal decompressions and fusions out of costly hospital settings, providing significant savings for payers and a more efficient patient experience, a rapid growth in outpatient capacity supported by a December 2024 survey by Compass Surgical Partners, where 53% of ASC leaders were planning to expand their spine service lines in 2025 to meet rising demand. Simultaneously, the acceleration of regenerative medicine and cell-based therapies is tackling the critical clinical issue of pseudarthrosis by improving biological fusion rates, especially in patients with poor bone quality; manufacturers are increasingly focusing on developing and commercializing advanced bone growth therapies and bioactive matrices that promote osteogenesis more effectively than traditional autografts, with this emphasis on biological effectiveness yielding significant commercial benefits as Orthofix Medical Inc. reported record net sales of $63.9 million for their Bone Growth Therapies segment in Q4 2024 (February 2025), a 9% increase year-over-year, underscoring the market's growing reliance on complementary solutions for achieving durable spinal stability.

Key Market Players

• Medtronic plc
• Johnson & Johnson Services, Inc.
• Stryker Corporation
• Zimmer Biomet Holdings, Inc.
• NuVasive, Inc.
• Globus Medical, Inc.
• Orthofix Medical Inc.
• SeaSpine Holdings Corporation
• RTI Surgical Holdings, Inc.
• Alphatec Holdings, Inc.

Report Scope

In this report, the Global Lumbar Degenerative Disc Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lumbar Degenerative Disc Disease Market, By Treatment Type

• Drug Treatment
• Biologics
• Other

Lumbar Degenerative Disc Disease Market, By Route of administration

• Oral
• Injectables
• Other

Lumbar Degenerative Disc Disease Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lumbar Degenerative Disc Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lumbar Degenerative Disc Disease Market.

Available Customizations:

Global Lumbar Degenerative Disc Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lumbar Degenerative Disc Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Drug Treatment, Biologics, Other)
  • 5.2.2. By Route of administration (Oral, Injectables, Other)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lumbar Degenerative Disc Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of administration
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lumbar Degenerative Disc Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of administration
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lumbar Degenerative Disc Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of administration
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lumbar Degenerative Disc Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of administration
      • 6.3.3.2.3. By End User

7. Europe Lumbar Degenerative Disc Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Route of administration
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lumbar Degenerative Disc Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of administration
      • 7.3.1.2.3. By End User
  • 7.3.2. France Lumbar Degenerative Disc Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of administration
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Lumbar Degenerative Disc Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of administration
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lumbar Degenerative Disc Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Route of administration
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lumbar Degenerative Disc Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Route of administration
      • 7.3.5.2.3. By End User

8. Asia Pacific Lumbar Degenerative Disc Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lumbar Degenerative Disc Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of administration
      • 8.3.1.2.3. By End User
  • 8.3.2. India Lumbar Degenerative Disc Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Lumbar Degenerative Disc Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of administration
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Lumbar Degenerative Disc Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Route of administration
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Lumbar Degenerative Disc Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Route of administration
      • 8.3.5.2.3. By End User

9. Middle East & Africa Lumbar Degenerative Disc Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lumbar Degenerative Disc Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of administration
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Lumbar Degenerative Disc Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of administration
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Lumbar Degenerative Disc Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of administration
      • 9.3.3.2.3. By End User

10. South America Lumbar Degenerative Disc Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lumbar Degenerative Disc Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of administration
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Lumbar Degenerative Disc Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Lumbar Degenerative Disc Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of administration
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lumbar Degenerative Disc Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Services, Inc.
• 15.3. Stryker Corporation
• 15.4. Zimmer Biomet Holdings, Inc.
• 15.5. NuVasive, Inc.
• 15.6. Globus Medical, Inc.
• 15.7. Orthofix Medical Inc.
• 15.8. SeaSpine Holdings Corporation
• 15.9. RTI Surgical Holdings, Inc.
• 15.10. Alphatec Holdings, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer